Delivery is perhaps the biggest hurdle for those racing to develop RNAi therapeutics — so much so that developing solutions to the problem has become a virtual cottage industry. Companies including Intradigm and Mirus have been working on delivery for some time, while others, such as newcomer Nastech, are just starting to get in on the action (see RNAi News, 2/6/2004).
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
You may already have institutional access!
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Not ready for premium?
Register for Free ContentYou can still register for access to our free content.